Zura Bio's tibulizumab for HS

Kaveri reviews Zura's IL-17/BAFF fused tibulizumab, affinity concerns, HS phase II data due in Q4, and Lilly's ROFN.

Play episode from 12:09

Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!